3 June 2020 – A brief commentary about Spike protein as an optimal immunological target for vaccines

In this commentary, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, which has proved to be highly immunogenic and capable of eliciting a robust neutralizing response.

As it rapidly became the main target of neutralizing antibodies and the focus of therapeutic and vaccine design, the Spike protein is considered as an ideal target for COVID-19 immunotherapy.

Full article: SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

22 May 2020 – Takis on “Il Fatto Quotidiano”: inside the Italian labs working on the Covid-19 vaccine

Takis has been mentioned in the video reportage on “Il Fatto Quotidiano” dedicated to the three Italian companies based near Rome that are working on the development of a Covid-19 vaccine. We and our colleagues are developing  different technologies and platforms but share the same goal: fighting the coronavirus.

Our DNA-based technology  is very promising and has several advantages in terms of scalability, adaptability and costs.

Watch the full video: https://bit.ly/2Xo3pNV



18 May 2020 – Takis on Repubblica TV special “Meet the future”

Luigi Aurisicchio, CEO of Takis, has been a host on the special “Meet the future” about biotech and coronavirus, organized by Repubblica TV in collaboration with Assobiotec.

Scientists, entrepreneurs and politicians discussed the role of biotechnology in the fight against coronavirus in Italy and their contribution in the redesign of a new post-Covid economic system. The first part, "The battle against the virus", had as guests Silvio Brusaferro, president of the Istituto Superiore di Sanità, Walter Ricciardi, consultant to the Minister of Health for the Covid emergency, Luigi Aurisicchio, CEO of Takis Biotech, Rino Rappuoli , scientific director of GlaxoSmithKline Vaccini, and Carlo Rosa, managing director of the DiaSorin group.

Aurisicchio described our DNA-based vaccine platform for Covid-19 disease, which allows for rapid manufacturing and targeting of virus mutations.

Watch the full special: https://bit.ly/3gKz6c3


9 May 2020 – Takis announces Neomatrix, a company fully dedicated to personalized cancer vaccines

NEOMATRIX is a individualised therapeutic cancer vaccine against tumour specific antigens, called neoantigens, arising from somatic gene mutations in malignant cells during neoplastic transformation. The tailored vaccine is intended for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours.

The process:

  • Tumor Biopsies are taken from patient
  • RNA and DNA are sequenced by Next Generation Sequences
  • Neoantigens are identified through a pipeline called NARciso
  • Codon Optimized Vaccine is synthesized in Takis Laboratories
  • 100-150mg DNA plasmids are manufactured in GMP conditions

The entire process is predicted to be back to the patient in 6 weeks.

For more information: www.neomatrixbiotech.com

Takis vaccines neutralize SARS-CoV-2

After inducing antibodies in animal models, Takis vaccines have proven effective in neutralizing the SARS-CoV-2 virus, thanks to the collaboration with the Spallanzani Institute in Rome

"The results obtained to date are encouraging and well beyond expectations: after a single vaccination, the mice developed antibodies that can block the infection of SARS-CoV-2 on human cells" - declares Luigi Aurisicchio, CEO / CSO of the Takis.

INMI (National Institute of Infectious Diseases) Lazzaro Spallanzani was among the first institutes in the world to isolate SARS-CoV-2 and represents an Italian excellence in the field of infectious diseases. Thanks to the neutralization test developed, it is possible to verify the efficacy of vaccines and therapeutic molecules directly on the virus, without using artificial systems. It is therefore possible to study the quality and power of the immune response necessary to block the infection and the spread of SARS-CoV-2.

"The molecular design of our vaccines took into account a series of important parameters to generate functional antibodies against the Spike protein, in particular against the region that binds to human lung cells" - says Giuseppe Roscilli, Director of the Monoclonal Antibodies Area.

To date, the immune response generated by most of our 5 candidates has an effect on the virus. We expect even better results after the second vaccination "- comments Emanuele Marra, director of the Infectious Diseases Area.

Takis' technology consists of the injection of a DNA fragment, followed by a short electrical stimulus. The technology is called "electroporation" and was developed in Italy. "One of the important characteristics of our vaccine is that it can be repeated over time and adapted to the evolution of the virus. At Takis, we are already working on a process that can be changed in a few weeks, if the virus accumulates mutations and becomes invisible to the immune system: the same concept that we use to develop cancer vaccines. " - states Fabio Palombo, director of the NeoMatrix program.

“Thanks to Spallanzani's skills, as far as we know, we are the first in the world to have demonstrated the neutralization of the coronavirus by a vaccine. We expect this to happen also in humans. We are also exploring other interesting technology platforms in collaboration with LineaRx, an American company. Some vaccines have received significant funding and have already started the clinical phase in other countries. We are working hard to make sure that a vaccine that comes from Italian research, with an entirely Italian and innovative technology, is tested in Italy and made available to everyone. To do this, we need the support of institutions and partners to help us speed up the process: this is not a race, and together we can all win against the coronavirus "- concludes Aurisicchio.